Home » Topics » BioWorld Science

BioWorld Science
RSS

Fujifilm describes new compounds for adenovirus infections

Feb. 14, 2020

Arcus Biosciences divulges adenosine A2A and/or A2B receptor antagonists

Feb. 14, 2020

XyloCor begins first-in-human study of XC-001 gene therapy for refractory angina

Feb. 14, 2020

IMP-4297 studied in phase III as maintenance treatment for advanced ovarian cancer

Feb. 14, 2020

MedImmune presents phase I data on MEDI-3726 in patients with mCRPC

Feb. 14, 2020

Role of microglia in memory loss elucidated

Feb. 14, 2020

Focused ultrasound enhances BBB delivery of TrkA receptor ligands for treating neurodegeneration

Feb. 14, 2020

Phase I/II data presented for SHR-3680 in metastatic castration-resistant prostate cancer

Feb. 14, 2020

Modified cyclodextrins show promising activity against multiple viral infections

Feb. 14, 2020

First-in-human data presented for m102.4

Feb. 14, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...